Q2 EPS Estimates for Editas Medicine Raised by HC Wainwright

Editas Medicine, Inc. (NASDAQ:EDIT) – Equities researchers at HC Wainwright lifted their Q2 2026 earnings per share estimates for shares of Editas Medicine in a research report issued to clients and investors on Tuesday, May 26th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.32) per share for the quarter, up from their prior estimate of ($0.34). The consensus estimate for Editas Medicine’s current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Editas Medicine’s Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($1.04) EPS, Q1 2027 earnings at ($0.33) EPS, Q2 2027 earnings at ($0.33) EPS and Q4 2027 earnings at ($0.15) EPS.

EDIT has been the subject of a number of other reports. JonesTrading raised Editas Medicine from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a report on Tuesday, March 10th. Robert W. Baird set a $6.00 target price on Editas Medicine in a report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Editas Medicine in a report on Monday, April 20th. Chardan Capital upped their target price on Editas Medicine from $3.50 to $4.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Wall Street Zen lowered Editas Medicine from a “hold” rating to a “sell” rating in a report on Sunday, May 10th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Editas Medicine presently has an average rating of “Moderate Buy” and a consensus target price of $5.40.

Editas Medicine Stock Performance

Shares of EDIT opened at $3.57 on Thursday. The stock has a 50 day moving average price of $2.83 and a two-hundred day moving average price of $2.43. The firm has a market capitalization of $349.54 million, a P/E ratio of -2.90 and a beta of 2.14. Editas Medicine has a 52 week low of $1.60 and a 52 week high of $4.54.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $2.83 million during the quarter, compared to analyst estimates of $6.37 million. Editas Medicine had a negative return on equity of 677.39% and a negative net margin of 281.59%.

Hedge Funds Weigh In On Editas Medicine

Several institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its stake in Editas Medicine by 30.7% in the first quarter. Renaissance Technologies LLC now owns 3,972,160 shares of the company’s stock valued at $9,811,000 after purchasing an additional 932,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Editas Medicine by 122.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock valued at $3,016,000 after purchasing an additional 1,430,000 shares during the last quarter. Geode Capital Management LLC lifted its stake in Editas Medicine by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 2,284,740 shares of the company’s stock valued at $4,685,000 after purchasing an additional 244,574 shares during the last quarter. State Street Corp lifted its stake in Editas Medicine by 2.6% in the fourth quarter. State Street Corp now owns 1,974,931 shares of the company’s stock valued at $4,049,000 after purchasing an additional 49,887 shares during the last quarter. Finally, Two Sigma Investments LP lifted its stake in Editas Medicine by 63.3% in the third quarter. Two Sigma Investments LP now owns 1,584,155 shares of the company’s stock valued at $5,497,000 after purchasing an additional 614,229 shares during the last quarter. Hedge funds and other institutional investors own 71.90% of the company’s stock.

Key Editas Medicine News

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: Investors showed strong speculative interest, with unusually heavy call buying suggesting some traders are positioning for further upside in Editas Medicine (EDIT).
• Positive Sentiment: HC Wainwright reiterated a bearish earnings outlook but the note did not materially worsen the company’s already negative profit profile, while keeping attention on future pipeline execution rather than near-term earnings.
• Positive Sentiment: Editas reported promising preclinical data for EDIT-401, showing ~90% or greater reductions in LDL-C, Lp(a), and ApoB in non-human primates, which supports the drug’s potential in hyperlipidemia and cardiovascular risk reduction. Article Title
• Positive Sentiment: The company also said it is on track to submit a clinical trial notification by mid-2026 and expects early human proof-of-concept data by year-end, which may reinforce optimism around its lead program. Article Title
• Negative Sentiment: Editas priced an underwritten public offering of more than 55.5 million shares plus warrants, which is pressuring the stock because it increases dilution risk for existing shareholders. Article Title
• Negative Sentiment: The company also suspended and terminated a prior at-the-market offering program, underscoring its ongoing need to raise capital and highlighting financing overhangs. Article Title

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.